Freeze date: 13 May 2026. Total: ~64,800 words across thirteen chapters (~162 printed pages).
This is the master entry point for a thirteen-chapter, ~162-page review of post-2010 psychedelic developments — clinical trials, receptor biology and neuroplasticity, the post-Lykos regulatory landscape, set-and-setting research, Indigenous-reciprocity ethics, microdosing’s largely-null controlled literature, and the methodological caveats every flagship trial inherits. The chapters are linked at the bottom of this post.
Scope
Five compound classes:
- Psilocybin / psilocin
- N,N-DMT
- LSD
- 5-MeO-DMT (mebufotenin) pharma program — Beckley/atai BPL-003; GH Research GH001
- Fluoroethyl lysergamides — FLUORETH-LAD, FP-LAD; with the “1Fe-LSD” ferrocenyl naming collision honestly flagged
Four emphasis dimensions, all heavily weighted: clinical evidence & methodology critique; mechanism (neuroplasticity & receptor biology); cognitive enhancement & microdosing (placebo-honest); sociocultural / Indigenous reciprocity / regulatory landscape.
Out-of-scope (sidebars only): ibogaine, ketamine, mescaline, MDMA-assisted therapy (Lykos as case study only), salvinorin A, 2C-x phenethylamines, ayahuasca clinical landscape.
Executive summary
The post-2010 psychedelics field arrives at mid-2026 in a position the 2018 enthusiasm did not predict and the 2024 Lykos collapse did not foreclose. It is neither the revolutionary breakthrough nor the failed paradigm; it is a serious clinical and regulatory enterprise with replicated Phase 3 efficacy in psilocybin for treatment-resistant depression, mature late-stage programmes across multiple indications, mechanistic convergence on a neuroplasticity model, and a small but real adult-use regulatory infrastructure — operating under methodological constraints the field has not yet solved.
Clinical pipeline status. The single most consequential 2025–2026 development is Compass Pathways’ replicated Phase 3 readout. COMP005 (announced 23 June 2025; n=258; single 25 mg dose vs placebo at 32 US sites) reported a placebo-adjusted MADRS reduction of −3.6 points at Week 6 (p<0.001). COMP006 (announced 17 February 2026; total dosed n=581 across three arms — 25 mg n=296, 10 mg n=142, 1 mg n=143; primary endpoint compared 25 mg vs 1 mg) replicated at −3.8 MADRS at Week 6, with durability data reported through Week 26. An NDA submission is planned for Q4 2026. The Lykos midomafetamine programme proceeded on a different trajectory: positive Phase 3 (MAPP1 2021, MAPP2 2023), then 2-9 against effectiveness at the 4 June 2024 FDA AdCom, ICER’s 14-1 inadequacy verdict, three Psychopharmacology retractions, a Complete Response Letter (9 August 2024), and a ~75% workforce reduction. The other late-stage programmes — MindMed MM120 in GAD (Phase 2b JAMA 2025; Phase 3 enrolling), Cybin CYB003 deuterated psilocybin (BTD 13 March 2024), Beckley/atai BPL-003 intranasal mebufotenin (Phase 2b met July 2025; BTD October 2025; merger November 2025), GH Research GH001 inhaled mebufotenin (Phase 2b met February 2025; placebo-adjusted MADRS −15.5, the largest in any psychedelic depression trial), and Reunion luvesilocin RE104 in postpartum depression (Phase 2 met August 2025; BTD February 2026) — continue under capital and regulatory constraints sharpened by the Lykos episode.
Mechanistic convergence on the neuroplasticity frame. The intracellular-5-HT2A thesis (Vargas et al., Science 2023) has become the dominant explanation for how classical psychedelics produce effects extending beyond the acute trip. Lipophilic ligands cross the neuronal membrane to engage intracellular 5-HT2A receptors on Golgi/ER membranes — receptors inaccessible to extracellular serotonin, which is why SSRI-induced 5-HT elevation does not produce psilocybin-comparable dendritic-spine growth. The cascade (TrkB / mTOR / BDNF with structural plasticity downstream) is the same one implicated in ketamine’s rapid antidepressant action, placing classical psychedelics in a broader “psychoplastogen” class. The Olson lab’s empirically discovered non-hallucinogenic 5-HT2A agonists (AAZ-A-154, tabernanthalog, the Delix isotryptamine series including DLX-001/zalsupindole) and the Roth lab’s structurally validated β-arrestin-biased compounds (IHCH-7086, IHCH-7113) are the experimental probes that, in principle, will decide whether the subjective psychedelic experience is mechanistically necessary for clinical effect or merely co-occurrent with the molecular plasticity. DLX-001’s FDA clearance for an at-home Phase 2 design (October 2025) is the most significant translational signal to date.
Microdosing as expectancy-dominated. The placebo-controlled microdosing literature — Szigeti 2021 (self-blinded citizen-science, n=191), Cavanna 2022 (real EEG theta-band changes with no behavioural benefit), de Wit/Molla 2022 (broadly null), and the Polito & Liknaitzky 2024 synthesis — has largely failed to dissociate active microdose from placebo on the outcomes that matter to users (mood, cognition, creativity). Neurophysiological signals are real (theta-band EEG change, amygdala connectivity shifts, time-perception dilation); behavioural translation is null in controlled designs. The honest verdict is that expectancy dominates: the active-versus-placebo gap is small, the placebo-versus-no-treatment gap is substantial, and expectancy is itself a legitimate psychological mechanism whose contribution to all psychiatric-treatment response is well-established. The chronic-dosing 5-HT2B / valvulopathy question remains the principal open safety concern, with the Tagen 2023 in silico safety margins narrow for LSD and psilocin under chronic protocols and no echocardiographic cohort study yet conducted.
Regulatory landscape. Five jurisdictions matter at mid-2026. Oregon Measure 109 (effective 1 January 2023) recorded 1,509 clients in Q1 2025 across 25 of 34 operational service centres. Colorado Proposition 122 rules were finalised June–August 2025; first healing centres are launching late 2025 / early 2026. Australia’s TGA Schedule 8 reclassification (effective 1 July 2023) has accumulated ~134 patients (87 MDMA-AT for PTSD; 47 psilocybin for TRD) across 13 authorised prescribers in five states through September 2025, with out-of-pocket cost the dominant barrier. The EU and UK have moved on policy rather than statute: Czechia passed medical psilocybin legislation in June 2025, Germany’s BfArM approved an EU-first compassionate-use programme in July 2025, the UK MHRA waived parallel domestic controlled-drug licensing for approved studies in July 2025. Canada’s Section 56(1) class exemption for clinical-trial at-home administration took effect 20 September 2025. The Massachusetts Question 4 defeat (November 2024, 57–43) shifted the US grassroots track toward legislative routes.
Methodological caveats. Every flagship Phase 3 psychedelic trial scores “high risk of bias” on Cochrane RoB 2’s outcome-measurement domain (D4) because functional unblinding is structurally unavoidable. ≥85% of active-arm participants correctly identify their assignment, often within an hour; rater blinding is permeable; primary endpoints are participant- or clinician-rated symptom scales. Applying Muthukumaraswamy’s 2021 expectancy-correction framework under plausible blinding-success differentials compresses COMP005’s headline −3.6 MADRS to a pharmacology-only residual of approximately −1.8 (and at the high end, nullified). COMP001 reported three suicide-related adverse events in the 25 mg arm; the cross-trial signal does not establish a clear elevation above disease-background but the power to rule one out is poor. The Lykos episode functions as a structural diagnosis: spousal therapist dyads (Yensen and Dryer), unreviewed dosing-session video supervision, MP-4 site protocol violations entangled with Phase 2 pooled-analysis data, three retracted papers, ICER’s separately reached unblinding-and-conduct critique.
The 5-MeO-DMT pharma program (Beckley/atai BPL-003 and GH Research GH001) is the highest-profile late-stage analog to the classical psychedelic pipeline. GH001’s −15.5 MADRS placebo-adjusted reduction is approximately 4× larger than Compass’s Phase 3 effects; the report decomposes this into four candidate explanations (baseline severity inflation, functional unblinding, IDR cumulative-dose dynamics, very-short outcome-window timing) and concludes a pharmacology-only residual of approximately −1 to −3.5 MADRS — within range of the Compass effect — pending Phase 3 replication.
Indigenous reciprocity. The Western clinical evidence base depends on knowledge derived from Mazatec, Wixárika, Shipibo-Konibo, NAC, and (in contested form) Comcáac practices. The post-2018 commercial-stage psychedelic pipeline has, to date, not produced revenue-tied structural obligations to the source communities. The report names specific compounds, communities, and pharma beneficiaries, with documented (or absent) reciprocity commitments per developer. The “psychedelic colonialism” critique is taken seriously across multiple chapters, not ghettoised in a single section. The 5-MeO-DMT toad ceremony — sometimes presented as ancient Mexican Indigenous practice — is, in the form practiced since the 1980s, a Western neoshamanic invention; the report cites the relevant Comcáac (Seri) and ethnobotanical record directly.
Open questions. Durability beyond six months is undetermined at population scale. The non-hallucinogenic 5-HT2A agonist clinical question is the field’s central decoupling test. Trial designs that survive functional unblinding require regulatory-science work the field has not yet done. Indigenous reciprocity remains an unresolved structural gap between commercial-stage rhetoric and contractual reality. Chronic 5-HT2B agonism’s cardiac risk is uncharacterised by any prospective human echocardiographic cohort.
The posture appropriate to a 2026 reader is sober, evidence-graded, and structurally honest about what the controlled literature does and does not establish. The chapters develop that posture in detail.
Chapters
| Ch | Title | One-sentence summary |
|---|---|---|
| I | Historical arc and sociocultural reframing | Traces the field from Hofmann’s 1943 LSD synthesis through Schedule I, the 1990s–2000s renaissance triggers, 2010s mainstreaming, and the 2024 Lykos correction. |
| II | Chemistry and pharmacology | Structural scaffolds, synthesis, stability, and pharmacokinetics for psilocybin/psilocin, DMT, LSD, 5-MeO-DMT, and the fluoroethyl lysergamides. |
| III | Receptor biology and signaling bias | Why 5-HT2A is necessary but not sufficient; Gq vs β-arrestin; the 2022–2025 cryo-EM atlas; the non-hallucinogenic 5-HT2A agonist frontier. |
| IV | Systems neuroscience and mechanism | DMN disintegration; entropy; REBUS; the dendritic-spine plasticity literature; the intracellular 5-HT2A thesis; durable connectivity changes. |
| V | Clinical evidence: depression and anxiety | Psilocybin TRD/MDD programme; LSD anxiety; MM120 GAD; meta-analytic comparison; Cochrane RoB 2.0 critique; ketamine as comparator. |
| VI | Clinical evidence: addiction, PTSD, anorexia, OCD | Psilocybin in AUD and tobacco cessation; MAPP1/MAPP2 MDMA-AT case study; the small-sample signals; ibogaine sidebar. |
| VII | Mebufotenin (5-MeO-DMT) clinical program | Two competing Phase 2b programmes — BPL-003 and GH001 — and the implausibly-large GH001 effect-size decomposition. |
| VIII | Fluoroethyl lysergamides | Structural pharmacology and harm-reduction epistemology of FLUORETH-LAD, FP-LAD, and the 1Fe-LSD ferrocenyl naming collision. |
| IX | Cognitive enhancement and microdosing | The placebo-controlled literature; the expectancy-dominated honest verdict; real neurophysiology without behavioural translation; chronic 5-HT2B safety. |
| X | Therapy model, set and setting, Indigenous reciprocity | Hartogsohn framework; music’s role; credentialing patchwork; differentiated Indigenous traditions; structural reciprocity gap. |
| XI | Regulatory and legal landscape | US federal status; the FDA BTD timeline; the Lykos regulatory episode; Oregon Measure 109; Colorado Prop 122; Australia, EU/UK, Canada; pharma economics. |
| XII | Methodology, adverse events, and ethics | Cochrane RoB 2.0 applied to the flagship trials; functional unblinding; suicidality and HPPD; the Lykos MP-4 misconduct forensics. |
| XIII | Synthesis & outlook | Convergent findings; open questions; five-to-ten year research agenda; reflexive acknowledgment of Western-academic sourcing. |
Reading-order recommendations
- Clinical pharmacology / psychiatry / clinical investigation. Ch V → Ch VI → Ch VII → Ch XII → Ch XIII.
- Neuroscience / psychopharmacology. Ch II → Ch III → Ch IV → open-questions section of Ch XIII.
- Regulatory science / policy. Ch I → Ch XI → Ch XII → Ch XIII §13.4.
- Medical anthropology / Indigenous studies / sociology. Ch I → Ch X → Ch XI §§11.3–11.5 → Ch XII §§12.8–9 → Ch XIII §13.4.
- End-to-end reading. I → II → III → IV → V → VI → VII → VIII → IX → X → XI → XII → XIII; approximately one long working day.
A note on verification
The report’s citations were processed through a full-sweep Gate-1 citation verifier (~350 PMIDs, DOIs, and ClinicalTrials.gov NCT IDs against PubMed and CrossRef), then through two adversarial-critique passes simulating five expert reviewer personas (clinical pharmacologist, biostatistician, medical anthropologist, regulatory scientist, Indigenous-studies scholar). Every attack point identified by those passes — 33 from Pass 1, 25 from Pass 2 — is addressed in the chapter texts. Specific citation-level corrections discovered during drafting are documented inline where load-bearing. A short discussion of the production rigor and residual caveats accompanies any panel-facing distribution.
The chapter texts below are the version of record as of the 13 May 2026 freeze date.